Wed, 4 May 2016
Healthcare: Digging Into Disappointment. What Investors Need To Know About Sarepta and Gilead Sciences' "Bad News"
Discussing the details behind the FDA's negative vote on Sarepta's DMD drug and Gilead Sciences' sliding hepatitis C sales. |